IP Library › Granted Patent US 8,163,295
Granted Patent B2
US 8,163,295 · App. 13/211,977 · Granted Apr 24, 2012

Outer membrane vesicles and uses thereof

Assignees: GlaxoSmithKline Biologicals S.A.; University of Utrecht
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,163,295
App. No.
13/211,977
Granted
Apr 24, 2012
Kind
B2
Abstract

The present invention discloses a Gram negative bacterium in which the expression of a protein involved in LPS transport to the outer membrane is functionally down-regulated such that the level of LPS in the outer membrane is decreased compared to a wild-type Gram negative bacterium. Down regulation of Imp and MsbA proteins can result in such a bacterium. Outer membrane vesicle preparations derived from the Gram negative bacterium of the invention can be used in vaccines to provide protection against bacterial infection.

Claims (2)

1. An outer membrane vesicle preparation from a Neisserial bacterium, wherein expression of the MsbA protein in said bacterium is functionally downregulated by disrupting the MsbA gene such that the level of lipopolysaccharide in the outer membrane is decreased compared to a wild-type Neisserial bacterium.

2. A pharmaceutical composition comprising the outer membrane vesicle preparation of claim 1 and a pharmaceutically acceptable carrier.

Priority Claims (2)
GB 0329827.0 · Dec 23, 2003 · national
GB 0416398.6 · Jul 22, 2004 · national
Continuity (3)
Continuation 12611393 · Nov 3, 2009
Continuation 10584362
Related Publication 20120039942A1 · Feb 16, 2012